Pikkelysömör: vizsgálatok itt: Olaszország
13 of 21 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 18.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
- Where
- Catania, Padova, Rome
- Életkor
- 4 év to 17 év
- People
- 210 worldwide
- Run by
- Takeda
See details and how to joinNCT07250802 · EU 2025-522567-15-00 - 3. fázisTaking peopleContinuation Study of Zasocitinib in Adults With Psoriatic Arthritis
- Where
- Ancona, Florence, Milan, Padova, Pisa, Rome, Rozzano
- Életkor
- 18 év and over
- People
- 1182 worldwide
- Run by
- Takeda
See details and how to joinNCT07286058 · EU 2025-522586-30-00 - 4. fázisBefejeződöttAn open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment
- Where
- Florence, Reggio Emilia
- People
- 339 worldwide
- Run by
- Novartis Pharma AG
See details and how to joinNCT04638647 · EU 2023-504417-67-00 - 3. fázisTaking peopleA Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Where
- Bergamo, Bologna, Rome, San Giovanni Rotondo, Trieste
- Életkor
- 3 év to 64 év
- People
- 196 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06663332 · EU 2023-509560-16-00 - 3. fázisTaking peopleLong-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
- Where
- Cagliari, Chieti Scalo, L'aquila, Modena, Naples, Rome, Rozzano
- Életkor
- 40 év and over
- People
- 3040 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07116967 · EU 2023-503766-24-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
- Where
- Bologna, Rome
- Életkor
- 12 év to 17 év
- People
- 366 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06979453 · EU 2023-506296-97-00 - 3. fázisTaking peopleA Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
- Where
- Florence, Milan, Rome
- Életkor
- 5 év to 17 év
- People
- 40 worldwide
- Run by
- AbbVie
See details and how to joinNCT06100744 · EU 2023-506026-36-00 - No phaseTaking peopleClinical Study on the Medical Devices PROXERA PSOMED 20 and PROXERA PSOMED 40 for the Treatment of Plaque Psoriasis and Non-pustular Palmoplantar Psoriasis
- Where
- Chieti
- Életkor
- 18 év to 65 év
- People
- 35
- Run by
- ICIM International S.r.l.
See details and how to joinNCT07545902 - No phaseTaking peopleClinical Study on the Medical Device PROXERA PSOMED 30 for the Treatment of Nail Psoriasis: Evaluation of Safety and Efficacy
- Where
- Chieti
- Életkor
- 18 év to 65 év
- People
- 21
- Run by
- ICIM International S.r.l.
See details and how to joinNCT07546032 - 3. fázisVisszavonvaA Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
- Where
- Cagliari, Ferrara, Milan, Naples, Novara
- Életkor
- 18 év and over
- People
- 320 worldwide
- Run by
- Janssen - Cilag International
See details and how to join2023-505121-14-00 - 3. fázisTaking peopleStudy to Assess Efficacy, Safety and Tolerability of a Nail Patch in Patients With Nail Fragility, Mychosis, Psoriasis
- Where
- Milan
- Életkor
- 18 év and over
- People
- 72
- Run by
- Wooshin Labottach Co., Ltd.
See details and how to joinNCT07029516 - No phaseTaking peopleDietary Approach to Mild-to-moderate Psoriasis
- Where
- Palermo
- Életkor
- 18 év to 65 év
- People
- 82
- Run by
- University of Palermo
See details and how to joinNCT05644782 - 4. fázisTaking peoplePotential Role of Guselkumab in Modulating PAIN Perception and Related Gene Pathways: a Proof-of-concept Study.
- Where
- Rome
- Életkor
- 18 év to 80 év
- People
- 26
- Run by
- Fondazione Policlinico Universitario Campus Bio-Medico
See details and how to joinNCT06974474